← Leaderboards
Albert F Candia
Dynavax Technologies Corporation
$1,123,962
Attributed
$1,235,657
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $589.5K · FY2013–17$1M$750K$500K$250K$0
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$1,235,657 · 2
By mechanism
R44$1,012,267 · 1
R41$223,390 · 1
Top collaborators
- Wajahat Zafar Mehal1 shared
Most similar at Dynavax Technologies Corporation
Same institution · by research overlap
- Franck Barrat$2,920,339
- Cristiana Guiducci$1,613,878
- Robert L Coffman$6,700,309
Others in their field
Top investigators on “Play”
- Lawrence Corey · Fred Hutchinson Cancer Center$428,785,907
- Chanza Baytop · Westat, Inc.$271,217,917
- Richard K. Wilson · Washington University$200,435,757
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Jeffrey P Krischer · University Of South Florida$191,869,794
- Constance Ann Benson · University Of California, San Diego$187,132,366
Research focus
PlayBasePharmaceutical PreparationsPublic Health RelevanceIn VivoIn VitroLeadPatternSystemic Lupus ErythematosusToll-Like ReceptorsNucleic AcidsLigandsAnimal ModelGenetic PolymorphismAutoimmunityAmino AcidsFundingHigh Throughput ScreeningCellsDrug DesignDendritic CellsAutoimmune DiseasesAutoimmune ProcessAutoantigens
Grant awards (3)
Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$422,785
R44 · FY2017 · AI · contact PI
Developing small molecule inhibitors of TLR8 for treatment of rheumatoid arthritis$589,482
R44 · FY2016 · AI · contact PI
The Development of TLR Antagonists for Therapy of Hepatic Fibrosis and Cirrhosis$223,390
R41 · FY2013 · DK · contact PI